144 related articles for article (PubMed ID: 8913847)
1. Octreotide as first-line treatment for women with metastatic breast cancer.
Ingle JN; Kardinal CG; Suman VJ; Krook JE; Hatfield AK
Invest New Drugs; 1996; 14(2):235-7. PubMed ID: 8913847
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.
Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN
Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
[TBL] [Abstract][Full Text] [Related]
4. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
Rose C; Kamby C; Mouridsen HT; Andersson M; Bastholt L; Møller KA; Andersen J; Munkholm P; Dombernowsky P; Christensen IJ
Breast Cancer Res Treat; 2000 May; 61(2):103-10. PubMed ID: 10942095
[TBL] [Abstract][Full Text] [Related]
5. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
Wenger FA; Zieren HU; Jacobi CA; Müller JM
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1348-50. PubMed ID: 9931878
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis.
Dolan JT; Miltenburg DM; Granchi TS; Miller CC; Brunicardi FC
Ann Surg Oncol; 2001 Apr; 8(3):227-33. PubMed ID: 11314939
[TBL] [Abstract][Full Text] [Related]
7. Bilateral swollen eyelids occurring during adjuvant treatment with tamoxifen for early breast cancer.
Jaspers H; Blaisse R; Maessen-Visch B; Mattijssen V
Neth J Med; 2009 Jun; 67(6):245-6. PubMed ID: 19749398
[No Abstract] [Full Text] [Related]
8. Adjuvant treatment of breast cancer.
Akerley WL
R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
[No Abstract] [Full Text] [Related]
9. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels.
Canobbio L; Cannata D; Miglietta L; Boccardo F
Anticancer Res; 1995; 15(6B):2687-90. PubMed ID: 8669848
[TBL] [Abstract][Full Text] [Related]
10. A rose is no longer a rose.
Henderson IC
J Clin Oncol; 2002 Aug; 20(16):3365-8. PubMed ID: 12177095
[No Abstract] [Full Text] [Related]
11. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
[TBL] [Abstract][Full Text] [Related]
12. [Metastatic breast carcinoma with neuroendocrine differentiation--its combined therapy with tamoxifen and the somatostatin analog octreotide].
Rischke HC; Staib-Sebler E; Mose S; Adams SW; Herrmann G; Böttcher HD; Lorenz M
Dtsch Med Wochenschr; 1999 Feb; 124(7):182-6. PubMed ID: 10093577
[TBL] [Abstract][Full Text] [Related]
13. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen for breast cancer.
Karn A; Jha AK; Shrestha S; Acharya B; Poudel S; Bhandari RB
JNMA J Nepal Med Assoc; 2010; 49(177):62-7. PubMed ID: 21180225
[TBL] [Abstract][Full Text] [Related]
15. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
Wenger FA; Jacobi CA; Siderow A; Zieren J; Zieren HU; Müller JM
Chirurg; 1999 Jun; 70(6):694-9. PubMed ID: 10427457
[TBL] [Abstract][Full Text] [Related]
16. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
[TBL] [Abstract][Full Text] [Related]
17. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
Bontenbal M; Foekens JA; Lamberts SW; de Jong FH; van Putten WL; Braun HJ; Burghouts JT; van der Linden GH; Klijn JG
Br J Cancer; 1998; 77(1):115-22. PubMed ID: 9459155
[TBL] [Abstract][Full Text] [Related]
18. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
[TBL] [Abstract][Full Text] [Related]
19. The potential role of somatostatin analogues in breast cancer treatment.
Pollak M
Yale J Biol Med; 1997; 70(5-6):535-9. PubMed ID: 9825480
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Lebowitz PF; Eng-Wong J; Widemann BC; Balis FM; Jayaprakash N; Chow C; Clark G; Gantz SB; Venzon D; Zujewski J
Clin Cancer Res; 2005 Feb; 11(3):1247-52. PubMed ID: 15709195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
